Intra-Cellular Therapies, Inc.
ITCI
Classifica tra le azioni
#1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Prezzo delle azioni
$131.87
Ultima sincronizzazione: 2025-04-02
Capitalizzazione di mercato
$12.68B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Intra-Cellular Therapies, Inc. (ITCI)
Categoria
Healthcare
EPS per Intra-Cellular Therapies, Inc. (ITCI)
EPS al December 2024 TTM: $-0.01
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Intra-Cellular Therapies, Inc., l’EPS attuale della società (TTM) è $-0.01. Alla fine del 2023, la società aveva un EPS di $-1.46 una diminuzione rispetto a rispetto a quello del 2022, che era di $-2.72.
Storico EPS per Intra-Cellular Therapies, Inc. da 2013 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
